The effect evaluation of highly active antiretroviral therapy to patients with AIDS in Hubei province of China

Abstract

The effects of highly active antiretroviral therapy (HAART) to patients with AIDS in Hubei province of China were investigated in order to provide scientific evidence to reinforce the management of HAART. Self-made questionnaires and descriptive method of epidemiology were used to collect and describe the changes of clinical symptoms, HIV RNA concentration, and immune function of patients with AIDS. After HAART, the effective rate of fever, cough, diarrhea, lymphadenectasis, weight loss, tetter, debility and fungous infection was 92.4%, 90.85%, 92.91%, 90.73%, 93.69%, 89.04%, 92.34%, and 83.1%, respectively. Of 117 patients with detected HIV RNA concentration, 41.03% had declined over 0.5 log, and 52.99% less than 0.5 log. CD4⁺T cell count was obviously increased: the average number after HAART for 3 or 6 months was 237/µL (26–755/µL) and 239/µL (17–833/µL), respectively. HAART can improve AIDS patients’ clinical symptoms, reduce HIV RNA concentration, and maintain immune function. It is very important for the effectiveness of HAART to raise clinical adherence of patients with AIDS and have a persistent surveillance.

Keywords

AIDS / highly active antiretroviral therapy / clinical adherence

References

[1] YeniP.. Update on HAART in HIV. J Hepatol, 2006, 44(1suppl): S100-S103

[2] Evaluation report on AIDS prevention and treatment of China in 2007. http://news.xinhuanet.com/health/2007-11/29/content_7166344.htm. Accessed 29 November 2007

[3] ZhangR.F., SunH.Q., LiuX.N., et al.. Observation of therapeutic efficacy of homestic antiretrovirus drugs for HIV/AIDS patients. World J Infect (Chinese), 2005, 5(2): 134-136

[4] WenY.. Review of AIDS treatment and bacteria research. Chin J Sch Health (Chinese), 2005, 6(26): 526-528

[5] LiuZ.. Antiviral therapy of AIDS. J Dermatol Venereol, 2005, 28(2): 14-20

[6] GibelliniD., BorderiM., De CrignisE., et al.. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals. J Infect, 2008, 56(3): 219-225

[7] ReM.C., RamazzottiE., ManfrediR., et al.. Viral load trend in HIV-1 seropositive patients with different CD4⁺T cell counts before starting HAART. J Clin Virol, 2000, 17(1): 5-11

[8] HeW.H., JinX.D., HeH.X., et al.. Change analysis on HIV-RNA concentration of HIV-infected patients. J Pub Health Prev Med (Chinese), 2006, 17(5): 95-96

[9] XuY.H., LiaoQ.H., WangC.J., et al.. Evaluation of the post-treatment highly active anti-retroviral therapy in AIDS patients. Chin J Epidemiol (Chinese), 2007, 28(7): 704-706

[10] EggerM., MayM., ChêneG., et al.. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, 2002, 360(9327): 119-129

[11] PakkerN.G., NotermansD.W., de BoerR.J., et al.. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med, 1998, 4(2): 208-214

[12] De CastillaD.L., VerdonckK., OteroL., et al.. Predictors of CD4⁺T cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. Int J Infect Dis, 2008, 12(3): 325-331

[13] BerenguerJ., Perez-EliasM.J., BellonJ.M., et al.. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naïve HIV-infected patients: results from a large multicenter observational cohort. J Acquir Immune Defic Syndr, 2006, 41(2): 154-159

[14] PulidoF., ArribasJ.R., MiroJ.M., et al.. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr, 2004, 35(4): 343-350

[15] ParientiJ.J., MassariV., DescampsD., et al.. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine or efavirenz-based antiretroviral therapy. Clin Infect Dis, 2004, 38(9): 1311-1316

[16] BangsbergD.R., HechtF.M., CharleboisE.D., et al.. Adherence to protease inhibitors, hiv-1 HIV RNA concentration and development of drug resistance in an indigent population. AIDS, 2000, 14(4): 357-366

[17] FlaksR.C., BurmanW.J., GourleyP.J., et al.. HIV transmission risk behavior and its relation to antiretroviral treatment adherence. Sex Transm Dis, 2003, 30(5): 399-404

[18] SpireB., DuranS., SouvilleM., et al.. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med, 2002, 54(10): 1481-1496